Ra’anana, Israel — August 14, 2025 — Leads & Copy — Polyrizon Ltd. (Nasdaq: PLRZ) has received confirmation from the Nasdaq Hearings Advisor that it has regained compliance with all applicable listing requirements.
In a letter dated August 13, 2025, the Hearings Advisor informed the company that it has demonstrated compliance with the minimum bid price requirement and satisfied the conditions of the Nasdaq Hearings Panel’s decision dated July 9, 2025.
The confirmation satisfies all conditions outlined by the Nasdaq Hearings Panel, and Polyrizon will continue to trade on the Nasdaq Capital Market under the ticker symbol “PLRZ.”
Polyrizon specializes in developing medical device hydrogels delivered as nasal sprays. The sprays form a shield barrier in the nasal cavity against viruses and allergens. Polyrizon’s Capture and Contain hydrogel technology functions as a biological mask. The company is further developing its C&C hydrogel technology for intranasal drug delivery, known as Trap and Target.
Michal Efraty, Investor Relations, IR@polyrizon-biotech.com
Source: Polyrizon
